Haemonetics claims first for blood salvage product
This article was originally published in Clinica
Haemonetics has received US clearance to sell a device for recovering blood loss in surgical patients that it believes broadens the types of patients who qualify for blood salvage.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.